Deutsche Bank Lowers Evotec Price Target to EUR 6, Keeps Hold Rating.

Deutsche Bank analyst Fynn Scherzler has lowered the price target on Evotec (EVO) to EUR 6 from EUR 7 and maintains a Hold rating. The move comes as part of a broader trend in the biotech sector, with many companies facing challenges in the wake of the COVID-19 pandemic. The analyst believes that Evotec's focus on developing novel therapies and diagnostics positions the company well for long-term growth, but notes that the current valuation is high.

Deutsche Bank analyst Fynn Scherzler has lowered the price target on Evotec (EVO) to EUR 6 from EUR 7 and maintains a Hold rating. This move comes as part of a broader trend in the biotech sector, with many companies facing challenges in the wake of the COVID-19 pandemic. Scherzler believes that Evotec's focus on developing novel therapies and diagnostics positions the company well for long-term growth, but notes that the current valuation is high [NUMBER:1].

Evotec's overall stock score is primarily affected by financial performance challenges, particularly in profitability and cash flow. Technical analysis provides some positive momentum, but valuation remains a concern due to negative earnings. Addressing profitability issues is key to improving the stock's outlook [NUMBER:1].

Analysts from RBC Capital, Deutsche Bank, and Warburg Research have a mixed outlook on Evotec. While RBC Capital and Warburg Research maintain a Buy rating, Deutsche Bank has a Hold rating. The average price target across these analysts is EUR 10.07, with a high forecast of EUR 11.90 and a low forecast of EUR 7.00. The average price target represents a 34.99% change from the last price of EUR 7.46 [NUMBER:1].

The analyst recommendation trends show that in the current month, EVT has received 6 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. The average analyst price target in the past 3 months is EUR 10.07 [NUMBER:1].

Evotec's financial forecasts indicate that the next quarter's earnings estimate is -€0.13 with a range of -€0.15 to -€0.08. The previous quarter's EPS was not provided, but Evotec beat its EPS estimate 0.00% of the time in the past 12 months. The sales forecast for the next quarter is EUR 197.73M with a range of EUR 189.20M to EUR 210.40M [NUMBER:1].

In summary, Deutsche Bank's Scherzler has lowered the price target on Evotec due to sector challenges and high valuation. Analysts have mixed ratings, with a focus on profitability and cash flow improvements. Investors should closely monitor Evotec's financial performance and address profitability issues to improve the stock's outlook.

References:
[1] https://www.tipranks.com/stocks/de:evt/forecast